Welcome to our dedicated page for Terns Pharmaceuticals news (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals stock.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) is a clinical-stage oncology company whose news flow centers on the development of TERN-701, a highly selective, oral, allosteric BCR-ABL (BCR::ABL1) inhibitor for chronic myeloid leukemia (CML). Company updates describe TERN-701 as the lead program in a focused oncology pipeline, with detailed disclosures on clinical data, regulatory interactions and trial design.
News about Terns frequently highlights results from the CARDINAL trial (NCT06163430), a global multicenter Phase 1/2 study of TERN-701 in previously treated chronic phase CML. Press releases and related SEC filings summarize major molecular response (MMR) and deep molecular response (DMR) rates, safety and tolerability findings, and outcomes in heavily pretreated or difficult-to-treat patient subgroups, including those with prior exposure to other tyrosine kinase inhibitors.
Investors following TERN can also find announcements about regulatory milestones, such as U.S. FDA Fast Track designation for TERN-701 in CML, and information on anticipated clinical priorities and program milestones. Terns’ news includes details on scientific presentations at major conferences like the American Society of Hematology (ASH) Annual Meeting and other healthcare conferences where updated CARDINAL data and development plans are discussed.
In addition, Terns issues news on capital markets activity, including underwritten public offerings of common stock intended to support research, clinical trials, development and manufacturing of key product candidates. Corporate updates may also cover decisions regarding legacy metabolic programs, such as TERN-501, TERN-801 and TERN-601, and the company’s strategy to seek partners for these assets. This news page aggregates such disclosures, offering a centralized view of Terns Pharmaceuticals’ clinical progress, financial developments and strategic focus in oncology.
Terns Pharmaceuticals, Inc. reported its first quarter 2024 financial results and corporate updates, highlighting the progress on its two lead programs, TERN-701 for CML and TERN-601 for obesity. The company has a cash position of $241 million expected to last into 2026. Recent developments include positive findings from the Phase 1 study of TERN-701 and the progress of TERN-601's first-in-human trial. The company also announced key appointments in its leadership team. Financially, Terns reported a net loss of $22.4 million for Q1 2024, with R&D expenses of $18.6 million and G&A expenses of $6.9 million.
Terns Pharmaceuticals, Inc. announced the appointment of Scott Harris as chief development officer and the departure of Erin Quirk, M.D., president, head of research and development. Dr. Quirk will be leaving the company to pursue other opportunities. Mr. Harris will oversee various operations, and key executives will now report directly to the CEO. The company expressed gratitude to Dr. Quirk for her contributions and confidence in the leadership team's ability to advance their pipeline. Mr. Harris brings over 25 years of experience in drug development and is optimistic about Terns' future.
Terns Pharmaceuticals, a clinical-stage biopharmaceutical company, will participate in The Citizens JMP Life Sciences Conference 2024. Senior management will join a fireside chat to discuss the company's small-molecule product candidates for serious diseases like oncology and obesity. The event will be live webcasted on May 14, 2024, at 1:30 p.m. ET, with a replay available for 30 days.
Terns Pharmaceuticals, Inc. announced the granting of an equity inducement award to Melita Sun Jung, the new Chief Business Officer, under the terms of the Inducement Plan. The award includes an option to purchase 475,000 shares of Terns common stock at an exercise price of $5.08 per share, with a 10-year term and vesting over four years.
Terns Pharmaceuticals, a biopharmaceutical company, announces positive data from a Phase 1 study of TERN-701, a potential BCR-ABL inhibitor for CML treatment, showing no food effect on dosing. The ongoing study in healthy volunteers displayed promising results, supporting once-daily dosing with or without food. The company aims to differentiate TERN-701 from the current standard, asciminib, by offering more convenient dosing options. Phase 1 CARDINAL trial is ongoing, with interim data expected in late 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.